亚铁血红素-铁蛋白系统作为贫血症和铁过载疾病的治疗靶点。
The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders.
机构信息
Department of Pulmonary & Critical Care Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
出版信息
Hematology Am Soc Hematol Educ Program. 2011;2011:538-42. doi: 10.1182/asheducation-2011.1.538.
Abstract
The review summarizes the current understanding of the role of hepcidin and ferroportin in normal iron homeostasis and its disorders. The various approaches to therapeutic targeting of hepcidin and ferroportin in iron-overload disorders (mainly hereditary hemochromatosis and β-thalassemia) and iron-restrictive anemias (anemias associated with infections, inflammatory disorders, and certain malignancies, anemia of chronic kidney diseases, and iron-refractory iron-deficiency anemia) are also discussed.
摘要
这篇综述总结了人们目前对血红素和亚铁转运蛋白在正常铁稳态及其紊乱中的作用的认识。本文还讨论了针对铁过载疾病（主要是遗传性血色素沉着症和β-地中海贫血）和缺铁性贫血（与感染、炎症性疾病和某些恶性肿瘤、慢性肾脏病相关的贫血以及铁难治性缺铁性贫血相关的贫血）中铁调素和亚铁转运蛋白的各种治疗靶向方法。
相似文献
1
The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders.亚铁血红素-铁蛋白系统作为贫血症和铁过载疾病的治疗靶点。
Hematology Am Soc Hematol Educ Program. 2011;2011:538-42. doi: 10.1182/asheducation-2011.1.538.
2
Hepcidin and disorders of iron metabolism.亚铁调素与铁代谢紊乱。
Annu Rev Med. 2011;62:347-60. doi: 10.1146/annurev-med-050109-142444.
3
The molecular basis of iron overload disorders and iron-linked anemias.铁过载疾病和铁相关性贫血的分子基础。
Int J Hematol. 2011 Jan;93(1):14-20. doi: 10.1007/s12185-010-0760-0. Epub 2011 Jan 7.
4
Regulation of hepcidin and iron-overload disease.铁调素的调控与铁过载疾病
Annu Rev Pathol. 2009;4:489-515. doi: 10.1146/annurev.pathol.4.110807.092205.
5
Hepcidin and iron homeostasis.铁调素与铁稳态。
Biochim Biophys Acta. 2012 Sep;1823(9):1434-43. doi: 10.1016/j.bbamcr.2012.01.014. Epub 2012 Jan 26.
6
Hepcidin in human iron disorders: therapeutic implications.人铁代谢紊乱中的铁调素：治疗意义。
J Hepatol. 2011 Jan;54(1):173-81. doi: 10.1016/j.jhep.2010.08.004. Epub 2010 Aug 26.
7
Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload.迷你肝铁素是经过合理设计的小肽，可模拟肝铁素在小鼠体内的活性，可能对治疗铁过载有用。
J Clin Invest. 2011 Dec;121(12):4880-8. doi: 10.1172/JCI57693.
8
Understanding the structure/activity relationships of the iron regulatory peptide hepcidin.了解铁调节肽铁调素的结构/活性关系。
Chem Biol. 2011 Mar 25;18(3):336-43. doi: 10.1016/j.chembiol.2010.12.009.
9
Hepcidin biology and therapeutic applications.铁调素的生物学特性及其治疗应用。
Expert Rev Hematol. 2010 Apr;3(2):153-5. doi: 10.1586/ehm.10.1.
10
An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.一种靶向 Tmprss6 的 RNAi 疗法可降低 Hfe(-/-) 小鼠的铁过载，并改善中间型 β-地中海贫血小鼠的贫血和铁过载。
Blood. 2013 Feb 14;121(7):1200-8. doi: 10.1182/blood-2012-09-453977. Epub 2012 Dec 6.
引用本文的文献
1
Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic Landscape.旧疗法，新问题：在药物治疗背景下重新思考放血疗法。
Pharmaceuticals (Basel). 2025 Aug 16;18(8):1212. doi: 10.3390/ph18081212.
2
A TMPRSS6-inhibiting mAb improves disease in a β-thalassemia mouse model and reduces iron in healthy humans.一种抑制TMPRSS6的单克隆抗体可改善β地中海贫血小鼠模型的病情，并降低健康人体内的铁含量。
JCI Insight. 2025 Jun 23;10(12). doi: 10.1172/jci.insight.191813.
3
Hepcidin inhibits hepatocyte apoptosis through the PERK pathway in acute liver injury and fibrosis.在急性肝损伤和肝纤维化中，铁调素通过PERK途径抑制肝细胞凋亡。
Hepatol Commun. 2024 Dec 20;9(1). doi: 10.1097/HC9.0000000000000604. eCollection 2025 Jan 1.
4
Sevuparin strongly reduces hepcidin expression in cells, mice, and healthy human volunteers.舍托肝素能显著降低细胞、小鼠和健康人类志愿者体内的铁调素表达。
Hemasphere. 2024 Nov 28;8(12):e70035. doi: 10.1002/hem3.70035. eCollection 2024 Dec.
5
Iron Metabolism, Calcium, Magnesium and Trace Elements: A Review.铁代谢、钙、镁与微量元素：综述
Biol Trace Elem Res. 2025 Apr;203(4):2216-2225. doi: 10.1007/s12011-024-04289-z. Epub 2024 Jul 6.
6
Hepcidin, in contrast to heparin binding protein, does not portend acute kidney injury in patients with community acquired septic shock.与肝素结合蛋白不同，铁调素并不会预示社区获得性脓毒性休克患者发生急性肾损伤。
PLoS One. 2024 May 2;19(5):e0299257. doi: 10.1371/journal.pone.0299257. eCollection 2024.
7
Hepatic HDAC3 Regulates Systemic Iron Homeostasis and Ferroptosis via the Hippo Signaling Pathway.肝脏HDAC3通过Hippo信号通路调节全身铁稳态和铁死亡。
Research (Wash D C). 2023 Nov 30;6:0281. doi: 10.34133/research.0281. eCollection 2023.
8
Free Radical and Viral Infection: A Review from the Perspective of Ferroptosis.自由基与病毒感染：基于铁死亡视角的综述
Vet Sci. 2023 Jul 11;10(7):456. doi: 10.3390/vetsci10070456.
9
Associations between Oxidant/Antioxidant Status and Circulating Adipokines in Non-Obese Children with Prader-Willi Syndrome.普拉德-威利综合征非肥胖儿童氧化/抗氧化状态与循环脂肪因子之间的关联
Antioxidants (Basel). 2023 Apr 13;12(4):927. doi: 10.3390/antiox12040927.
10
Iron Metabolism in Cardiovascular Disease: Physiology, Mechanisms, and Therapeutic Targets.铁代谢与心血管疾病：生理、机制与治疗靶点。
Circ Res. 2023 Feb 3;132(3):379-396. doi: 10.1161/CIRCRESAHA.122.321667. Epub 2023 Feb 2.
本文引用的文献
1
Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice.证据表明，急性和慢性铁负荷在小鼠中通过不同途径调节铁调素。
Hepatology. 2011 Apr;53(4):1333-41. doi: 10.1002/hep.24178.
2
Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation.抑制骨形态发生蛋白信号可减轻炎症相关贫血。
Blood. 2011 May 5;117(18):4915-23. doi: 10.1182/blood-2010-10-313064. Epub 2011 Mar 10.
3
Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.在一项首次人体研究中，健康受试者中一种人源抗 IL-6 单克隆抗体（sirukumab）的药代动力学、药效学和安全性。
Br J Clin Pharmacol. 2011 Aug;72(2):270-81. doi: 10.1111/j.1365-2125.2011.03964.x.
4
Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice.Tmprss6 是小鼠 Hfe 遗传性血色素沉着症表型的遗传修饰因子。
Blood. 2011 Apr 28;117(17):4590-9. doi: 10.1182/blood-2010-10-315507. Epub 2011 Feb 25.
5
Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.利用铁调素作为治疗手段限制β-地中海贫血小鼠的铁过载并改善贫血。
J Clin Invest. 2010 Dec;120(12):4466-77. doi: 10.1172/JCI41717. Epub 2010 Nov 22.
6
Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo.肝素：体外和体内强效抑制铁调素表达。
Blood. 2011 Jan 20;117(3):997-1004. doi: 10.1182/blood-2010-06-289082. Epub 2010 Nov 12.
7
Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.贫血、无效红细胞生成和铁调素：导致β-地中海贫血中铁过载的异常铁代谢中的相互作用因素。
Hematol Oncol Clin North Am. 2010 Dec;24(6):1089-107. doi: 10.1016/j.hoc.2010.08.003. Epub 2010 Oct 15.
8
Hepcidin and disorders of iron metabolism.亚铁调素与铁代谢紊乱。
Annu Rev Med. 2011;62:347-60. doi: 10.1146/annurev-med-050109-142444.
9
Detection, evaluation, and management of iron-restricted erythropoiesis.铁缺乏性红细胞生成的检测、评估和管理。
Blood. 2010 Dec 2;116(23):4754-61. doi: 10.1182/blood-2010-05-286260. Epub 2010 Sep 8.
10
BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice.BMP6 治疗可补偿 Hfe 基因敲除小鼠的分子缺陷并改善其血色病。
Gastroenterology. 2010 Nov;139(5):1721-9. doi: 10.1053/j.gastro.2010.07.044. Epub 2010 Aug 1.
Zotero 插件